SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy.

ABSTRACT: Temozolomide (TMZ) is the primary chemotherapeutic drug for treating glioblastoma (GBM); however, the final clinical outcome is considerably limited by the poor response and resistance to TMZ. Although autophagy is thought to be associated with chemotherapy resistance and cancer cell survival, the precise molecular mechanisms underlying this process remain elusive. The suppressor of cytokine signaling (SOCS) family is widely distributed in vivo and exerts a range of effects on tumors; however, the expression pattern and role of SOCS in GBM remains unknown. In this study, we determined that high SOCS5 expression level was associated with poor prognosis and TMZ resistance in GBM. TMZ induced an increase in SOCS5 expression level and upregulated autophagy during the acquisition of drug resist

SUBMITTER: Yu J 

PROVIDER: S-EPMC9342142 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature